Much of the innovation regarding the healthcare sector has been focused on the development of novel drugs and therapies as well as diagnostics and devices. As the industry continues to evolve, innovation in areas such as prevention and more personalized care, as well as efficient technology-enabled care models may come into focus as well.
This year the global healthcare industry will record a growth rate of 4.82%, according to a report by ResearchAndMarkets.com. The report also included that, “the unique confluence of emerging technologies and investment trends will make 2018 the year of technical breakthroughs with the adoption of popular digital health technology solutions such as artificial intelligence (AI), Internet of Medical Things (IoMT), Big Data analytics, and robotics across select healthcare segments.”
As innovation and emerging technology continue to lead the sector, here are a few healthcare stocks to watch this month.
Premier Health Group, Inc. (PHGRF) (PHGI) provided an update on its expansion plans into the Cannabis clinic space by a series of acquisitions, partnerships and/or launching a new Canada-based chain in the first half of 2019. The company has engaged discussions with Licensed Producers under the Access to Cannabis for Medical Purposes Regulation (ACMPR), other licensed medical cannabis companies as well as government officials in order to establish a framework for both patient and physician education. Furthermore, the company is actively recruiting additional physicians for its existing clinics and a cannabis focused physician that is licensed in Canada.
“Cannabis clinics fit in perfectly with our existing Telemedicine services and comprehensive app plans. The patient will not only be able to see their family doctor with our app, but also connect with their Cannabis clinic healthcare worker, the education nurse and eventually even the pharmacy or LP that is providing the prescription. This team based and encompassing approach will provide the best and most convenient care for our patients” said Dr. Essam Hamza, CEO.
This is coming off the news that the company plans to enter the Pharmacy market via acquisition and/or launching a new Canada based pharmacy in H1–2019 and is actively reviewing a pipeline of additional pharmacy partners, including bricks and mortar locations and strategic new retail opportunities. Premier Health entered the primary care clinic and healthcare technology business via the HealthVue transaction, obtaining access to a group of four Greater Vancouver-based fully integrated medical clinics with a 10-year history, 22 health care professionals and over 110,000 active patients.
Tonix Pharmaceuticals Holding Corp. (TNXP) recently announced receiving the official minutes from the October 29th Breakthrough Therapy Type B Clinical Guidance meeting with the US FDA. The minutes are consistent with the preliminary guidance that Tonix had received at the meeting, confirming the FDA’s acceptance of the new Phase 3 “RECOVERY” study design evaluating Tonmya (TNX-102).
“The minutes from our Breakthrough Therapy Clinical Guidance meeting with the FDA are consistent with our previous assessment. We are moving forward expeditiously to initiate the RECOVERY study in the first quarter of 2019 and expect to have topline data in the first half of 2020” commented Seth Lederman, M.D., President and CEO.
Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense through potential medical counter-measures. The company’s pipeline includes: Tonmya, TNX-102 SL targeting Alzheimer’s disease under a separate IND to support a Phase 2, TNX-601 (tianeptine oxalate) is in the pre-IND application stage for PTSD, and TNX-801, a potential smallpox-preventing vaccine in the pre-IND application stage.
CorMedix, Inc. (CRMD) yesterday Elizabeth Masson EVP, Head of Clinical Operations purchased another 40, 000 shares of the company’s stock. This follows other insiders suchs as CEO Khoso Baluch acquired 25,000, CFO Robert Cook acquired 25,000 shares, and Myron Kaplan, a director purchased 50,000 shares at the end of last month.
CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Neutrolin®, a non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters, currently in Phase 3 development for patients undergoing chronic hemodialysis.
The company recently released Q3 financials and reported a loss of $10.2 million and on a per-share basis it had a loss of 11 cents. Revenue of $372,500 was reported in the period.
This Blog is an affiliate of Midam Ventures LLC. Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. MIDAM was hired for a period from 10/1/2018–4/1/2019 to publicly disseminate information about Premier Health Group Inc. Midam was paid $100,000 (CASH) & “500,000” shares of restricted common shares, they own zero shares that were purchased in the open market. Once the (6) six-month restriction is complete on 4/1/2018, Midam plans to sell the “500,000” shares of Premier Health Group Inc. that they hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Midam may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click here for full Midam disclaimer.
Biotech Breakroom 